Europe: In 2023, Amarin secured pricing and reimbursement and launched VAZKEPA in 3 additional markets, including Spain and the Netherlands. VAZKEPA is now available in 9 markets across Europe. Amarin delivered approximately 65% growth in the fourth quarter versus the third quarter 2023. In 2024, we will focus on opportunities to accelerate revenue in Europe in key launched markets including Spain and the United Kingdom, and advance pricing and reimbursement processes in key markets including Italy, France, and Germany. United States: In 2023, the Amarin team continued to retain its IPE market share leadership in the U.S. at 57%, despite additional generic competition. In 2024, we will focus on maintaining IPE market share leadership and profitability while continuing to adapt to dynamic market conditions. Rest of World: In 2023, the Amarin team secured 5 Rest of World regulatory approvals, including China, and entered into marketing and commercialization agreements in key markets and regions, including Australia & New Zealand and ASEAN/South Korea. In 2024, we will support pricing and reimbursement and commercialization efforts across key markets, including Australia and China, and continue to progress Rest of World regulatory filings.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on AMRN:
- Sarissa Capital sees Amarin shares as ‘meaningfully undervalued’, boosting stake
- Amarin reinstated with an Underweight at JPMorgan
- New REDUCE-IT® Analyses Show VASCEPA® (icosapent ethyl) Associated with 29 Percent Relative Risk Reduction Compared with Placebo in Prespecified Subgroup of Patients with Metabolic Syndrome, but Without Diabetes at Baseline
- Amarin announces results from new REDUCE-IT analyses
